PMID- 21773753
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20220330
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 459
IP  - 4
DP  - 2011 Oct
TI  - ERG gene rearrangement status in prostate cancer detected by 
      immunohistochemistry.
PG  - 441-7
LID - 10.1007/s00428-011-1128-4 [doi]
AB  - TMPRSS2-ERG, the most common gene fusion in prostate cancer, is associated with 
      expression of a truncated protein product of the oncogene ERG. A novel anti-ERG 
      monoclonal antibody has been recently characterized. We investigated the 
      correlation between ERG rearrangement assessed by fluorescence in situ 
      hybridization (FISH) and ERG expression detected by immunohistochemistry in a 
      large cohort of patients treated with radical prostatectomy for clinically 
      localized prostate cancer. Thirteen tissue microarrays comprising 305 tumors and 
      a subset of 112 samples of nonneoplastic prostatic tissue were assessed for ERG 
      rearrangement status by FISH and for ERG expression by immunohistochemistry. 
      Accuracy of ERG detection by immunohistochemistry in predicting ERG status as 
      assessed by FISH (criterion standard) was calculated in terms of sensitivity, 
      specificity, positive and negative predictive values. Of 305 tumor foci, 103 
      (34%) showed ERG rearrangement by FISH. ERG was detected by immunohistochemistry 
      in 100 (33%) cases, 99 of which were FISH positive. ERG detection by 
      immunohistochemistry demonstrated a sensitivity and specificity of 96% and 99%, 
      respectively, with positive and negative predictive values of 99% and 98%, 
      respectively. None of the 112 samples of nonneoplastic prostatic tissue was 
      rearranged by FISH or showed any ERG expression. In conclusion, ERG detection by 
      immunohistochemistry in prostate cancer was highly predictive of ERG 
      rearrangement as assessed by FISH in a large cohort of prostatectomy patients. 
      Given the high yield and the easier task of performing immunohistochemistry vs. 
      FISH, ERG assessment by immunohistochemistry may be useful for characterizing ERG 
      status in prostate cancer.
FAU - Falzarano, Sara Moscovita
AU  - Falzarano SM
AD  - Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, 
      USA.
FAU - Zhou, Ming
AU  - Zhou M
FAU - Carver, Paula
AU  - Carver P
FAU - Tsuzuki, Toyonori
AU  - Tsuzuki T
FAU - Simmerman, Kelly
AU  - Simmerman K
FAU - He, Huiying
AU  - He H
FAU - Magi-Galluzzi, Cristina
AU  - Magi-Galluzzi C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110720
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal
MH  - Gene Rearrangement
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*analysis/genetics
MH  - Prostatic Neoplasms/*genetics
MH  - Sensitivity and Specificity
MH  - Tissue Array Analysis
MH  - Trans-Activators/*analysis/genetics
MH  - Transcriptional Regulator ERG
EDAT- 2011/07/21 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/07/21 06:00
PHST- 2011/03/07 00:00 [received]
PHST- 2011/04/20 00:00 [accepted]
PHST- 2011/04/07 00:00 [revised]
PHST- 2011/07/21 06:00 [entrez]
PHST- 2011/07/21 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - 10.1007/s00428-011-1128-4 [doi]
PST - ppublish
SO  - Virchows Arch. 2011 Oct;459(4):441-7. doi: 10.1007/s00428-011-1128-4. Epub 2011 
      Jul 20.